Table 2.
Effectiveness of dupilumab: estimated (clinical) severity scores (ESS) over time
| The Netherlands | Japan | |||
|---|---|---|---|---|
| ESS (95% CI) | % change from baseline | ESS (95% CI) | % change from baseline | |
| Eczema Area and Severity Index score | ||||
| Baseline | 14·8 (9·9–19·7) | – | 23·8 (8·6–39·0) | – |
| 4 weeks | 9·4 (5·8–13·0) | –36·5 | 11·6 (0·6–22·6) | –51·3 |
| 12 weeks | 5·7 (3·9–7·5) | –61·5 | 5·3 (1·4–9·2) | –77·7 |
| 52 weeks | 4·9 (4·0–5·8) | –66·9 | 3·0 (2·0–4·0) | –87·4 |
| 80 weeks | 4·3 (2·9–5·7) | –70·9 | 3·6 (1·8–5·4) | –84·9 |
| Patient‐Oriented Eczema Measure score | ||||
| Baseline | 18·1 (17·0–19·2) | – | 14·1 (13·2–15·0) | – |
| 4 weeks | 11·3 (10·3–12·3) | –37·6 | 10·2 (8·7–11·7) | –27·7 |
| 12 weeks | 8·4 (7·4–9·4) | –53·6 | 6·0 (2·6–9·4) | –57·4 |
| 52 weeks | 8·4 (7·4–9·4) | –53·6 | 4·6 (3·4–5·8) | –67·4 |
| 80 weeks | 7·5 (6·3–8·7) | –58·6 | 4·4 (2·9–5·9) | –68·8 |
| Dermatology Life Quality Index score | ||||
| Baseline | 10·8 (9·9–11·7) | – | 7·8 (7·0–8·6) | – |
| 4 weeks | 6·3 (5·5–7·1) | –41·7 | 5·7 (4·5–6·9) | –26·9 |
| 12 weeks | 4·2 (3·4–5·0) | –61·1 | 3·3 (0·8–5·8) | –57·7 |
| 52 weeks | 4·0 (3·1–4·9) | –63·0 | 2·5 (1·5–3·5) | –67·9 |
| 80 weeks | 3·1 (2·0–4·2) | –71·3 | 2·0 (0·8–3·2) | –74·4 |
| Numeric Rating Scale‐pruritus | ||||
| Baseline | 6·6 (6·2–7·0) | – | 5·9 (5·5–6·3) | – |
| 4 weeks | 4·9 (4·5–5·3) | –25·8 | 4·5 (3·9–5·1) | –23·7 |
| 12 weeks | 3·9 (3·5–4·3) | –40·9 | 3·0 (1·8–4·2) | –49·2 |
| 52 weeks | 3·5 (3·1–3·9) | –47·0 | 2·6 (2·1–3·1) | –55·9 |
| 80 weeks | 3·2 (2·7–3·7) | –51·5 | 2·5 (1·9–3·1) | –57·6 |
| Thymus and activation‐regulated chemokine (TARC) levels a | ||||
| Baseline | – | – | 2239 (1553–2925) | – |
| 4 weeks | – | – | 578 (80–1076) | –75·3 |
| 12 weeks | – | – | 483 (87–878) | –79·4 |
| 52 weeks | – | – | 339 (259–419) | –85·5 |
| 80 weeks | – | – | 255 (49–461) | –89·1 |
CI, confidence interval.
a
Measured in pg mL–1.